|

Olomorasib Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: LY3537982

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Janssen Research & Development, LLC1
  • Eli Lilly and Company1

Indications

  • Carcinoma, Non-Small-Cell Lung2
  • Lung Cancer2
  • Cancer2

Huntsville, Alabama1 trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Irvine, California1 trial

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

University of California Irvine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.